Method of using (H+/K+) ATPase inhibitors as antiviral agents

Details Method of using (H+/K+) ATPase inhibitors as antiviral agents Method of using (H+/K+) ATPase inhibitors as antiviral agents

2005-06-14

2005-06-14

Kumar, Shailendra (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S307000, C514S322000

Reexamination Certificate

active

06906078

ABSTRACT:
A class of compounds which are (H+/K+)ATPase inhibitors can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula III:wherein D is N or CH; wherein R7is one or more radicals selected from hydrido, alkoxy, amino, cyano, nitro, hydroxyl, alkyl, halo, haloalkyl, carboxyl, alkanoyl, nitro, amino, alkylamino, amide, alkylamide, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; wherein R9is one or more radicals selected from hydrido, alkoxy, amino, alkyl, halo, cyano, nitro, hydroxyl, haloalkyl, carboxyl, alkanoyl, nitro, amine, alkylamine, dialkylamine, amide, alkylamide, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; and wherein R10and R11are independently selected from hydrido and alkyl; or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 4045563 (1977-08-01), Berntsson et al.
patent: 4045564 (1977-08-01), Berntsson et al.
patent: 4182766 (1980-01-01), Krassóet al.
patent: 4248880 (1981-02-01), Krasso et al.
patent: 4255431 (1981-03-01), Junggren et al.
patent: 4327102 (1982-04-01), Crossley
patent: 4337257 (1982-06-01), Junggren et al.
patent: 4359465 (1982-11-01), Ruwart
patent: 4371537 (1983-02-01), Markley et al.
patent: 4394509 (1983-07-01), Crossley
patent: 4472409 (1984-09-01), Senn-Bilfinger
patent: 4772619 (1988-09-01), Adelstein et al.
patent: 5198552 (1993-03-01), Trofimov et al.
patent: 5605919 (1997-02-01), Matsumori
patent: 5679695 (1997-10-01), Wassmundt
patent: 5945425 (1999-08-01), Moormann et al.
patent: 3415971 (1984-11-01), None
patent: 130 729 (1985-01-01), None
patent: 127 763 (1985-12-01), None
patent: 167 943 (1986-01-01), None
patent: 178 438 (1986-04-01), None
patent: 194 458 (1986-09-01), None
patent: 234 690 (1986-09-01), None
patent: 335 646 (1989-10-01), None
patent: 354 788 (1990-02-01), None
patent: 407 217 (1991-01-01), None
patent: 514 830 (1992-11-01), None
patent: 2134523 (1984-08-01), None
patent: 2161160 (1986-01-01), None
patent: 1230560 (1989-09-01), None
patent: WO 92/07867 (1992-05-01), None
Lindberg et al, TIPS, vol. 8, Oct. 1987, pp 399-402.
Lindberg et al., “Structure-activity relationships of omeprazole analogues and their mechanism of action.” Trends in Pharmaceutical Sciences, 1987, pp. 399-402, vol. 8, No. 10.
Hayashi et al., “In Vitro and in Vivo Antiviral Activity of Scopadulcic Acid B fromScoparia dulcis, Scrophulariaceae, Against Herpes Simplex Virus type1.” Antiviral Research, 1988, pp. 345-354, vol. 9.
Holsey et al., “Evidence for Poliovirus-Induced Cytoplasmic Alkalinization iN HeLa Cells.” J. of Cellular Physiology, 1990, pp. 586-591, vol. 142.
Hayashi et al., “Scopadulcic Acid B, a NEw Tetracyclic Diterpenoid fromScoparia dulcisL. Its Structure, H+, K+−Adenosine Triphosphatase Inhibitory Activity and Pharmacokinetic Behaviour in Rats.” Chem, Pharm, Bull., 1990, pp. 2740-2745, vol. 38, No. 1.
Hayshi et al., “Antiviral Agents of Plant Origin. II. Antiviral Activity of Scopadulcic Acid B Derivatives.” Chem, Pharm, Bull., 1990, pp. 239-242, vol. 38, No. 1.
Naruse et al., “Pumilacidin, A Complex of New Antiviral Antibiotics Production, Isolation, Chemical Properties. Structure and Biological Activity.” J. Antibodies, 1990, pp. 267-280, vol. 43, No. 3.
Ljungman et al., “Acyclovir-Resistant Herps Simplex Virus Causing Pneumonia after Marrow Transplantation.” J. Infec. Dis., 1990, pp. 244-248, vol. 162, No. 1.
Gately et al., “Herpes Simplex Virus Type 2 Meningoencephalitis Resistant to Acyclovir in a Patient with Aids.” J. Infect. Dis., 1990, pp. 711-715, vol. 161, No. 4.
Lui et al., “The Herpes Simplex Virus 1 Gene Encoding a Protease Also Contains within Its Coding Domain the Gene Encoding the More Abundant Substrate.” J. Virol., 1991, pp. 5149-5156, vol. 65, No. 10.
Welch et al., “A Herpesvirus Matirational Proteinase, assembling: Identification of its Gene, Putative active site domain, and cleavage site.” Proc. Natl. Acad. sci. USA, 1991, pp. 10792-10796, vol. 88, No. 23.
Altamirano et al., “Human Cytomegalovirus Infection Increases the Number of Ouabain-Binding Sites in Human Fibroblasts.” Virology, 1994, pp. 151-159, vol. 199.

Affiliated with

Also associated with

Rating

Method of using (H+/K+) ATPase inhibitors as antiviral agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of using (H+/K+) ATPase inhibitors as antiviral agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using (H+/K+) ATPase inhibitors as antiviral agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3515504